Venture Engineering: A New Alternative Investment for Family Offices
Gary Magnant, Partner, is a Boston-based serial biotechnology entrepreneur with a successful track record of starting, building and selling life science companies for more than 25 years. He conceived of and developed the Venture Engineering process and principles used by the Fund to manage portfolio company risks, build power-broker teams and exit faster than Venture Capital funds. Gary is the brainchild and co-founder of several successful biotech companies, including Owl Scientific (assigned by ThermoFisher, NYSE: TMO), Sage Science (Beverly, MA) and Thrive Bioscience (Wakefield, MA). He was also a co-founder of two venture-backed startup companies, ActivBiotics (>$100M invested) and ThermoCeramix ($>10M invested) which failed under the Venture Capital model and drove much of Gary’s inspiration for a better early stage investment model.
Gary is currently interim CEO and Venture Engineer at TriBiotica, a Triple Sharp portfolio company. He is a former chairman and member of the Board of Trustees of Stoneridge Montessori (now Harborlight Montessori), and a recipient of the institution’s most prestigious community service award, The Hallowell Award. Gary is the inventor on numerous life science and advanced materials patents, including a patent issued in 2017 covering an advanced cell and tissue culture systems.
Rahul Bhansali, Partner, is a dynamic, curious, and analytically-minded tech entrepreneur and marketer that founded / co-founded three companies in organic food home delivery, physical commodity trade consulting, and industrial safety technology. Most recently, he co-founded StrongArm Technologies (~$10m invested). There, he delivered a machine learning / IoT technology that is shown to produce massive savings for enterprise clients, to companies including some of the largest courier, retail, and ecommerce companies in the world. He orchestrated the creation of its category, Industrial BioTelemetrics, to improve safety and productivity of millions of workers worldwide. He has seen firsthand the pitfalls and inefficiencies of the Venture Capital model, instilling in him a passion to operate an improved early stage investment model. As Director of Indlak Group, Rahul has managed a number of his family’s enterprises. After bringing his foray into organic agriculture, Ehsaas Organic, well into profitability, he integrated it into his family companies. The Bhansali Family’s business assets, primarily located in India, are spread across a number of activities such as international trade, footwear manufacturing, real estate development, hospitality, and organic food production & lifestyle products. Rahul has an MBA from Babson, is an oil painter, is trained in Socratic method-based dialogue facilitation, and practices deep insight meditation.
W. Adam Hill, Partner, is focused on positively impacting patients’ lives and bringing efficiency and effectiveness to discovering new medicines.
Adam is a pioneer in the implementation of new technologies to effect greater efficiencies in life sciences. Prior to joining Triple Sharp, Adam served as a long-time head of drug screening for Novartis, one of the top pharmaceutical companies in the world. In this role, Adam advanced new compounds into clinical development and evaluated new drug discovery technologies. He also served as a managing scientist at Millennium Pharmaceuticals and Schering-Plough.
Adam received his D. Phil, Chemistry & Pharmacology, from the University of Oxford and conducted post-doctoral research at Harvard University and the University of Connecticut.
“Goodness is the only investment that never fails.”
– Henry David Thoreau